Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 14 of 14 entries
View as:

Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01392976 Org: User:
Start: 04/30/11 End: 04/30/13 Due: 04/30/14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02322281 Org: User:
Start: 02/28/15 End: 03/29/18 Due: 03/29/19

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT02630186 Org: User:
Start: 02/24/16 End: 09/05/17 Due: 09/05/18

Rociletinib (CO-1686) USA Expanded Access Program

Phase: N/A Priority: Normal
NCT ID: NCT02547675 Org: User:
Start: - End: - Due: -

A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin

Phase: N/A Priority: Normal
NCT ID: NCT01641575 Org: User:
Start: 07/31/12 End: 06/30/13 Due: 06/30/14

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02580708 Org: User:
Start: 09/30/15 End: 06/27/16 Due: 06/27/17

Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01233375 Org: User:
Start: 04/30/11 End: 03/31/13 Due: 03/31/14

A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02202746 Org: User:
Start: 09/09/14 End: 01/18/17 Due: 01/18/18

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase: N/A Priority: Normal
NCT ID: NCT01526928 Org: User:
Start: 03/27/12 End: 08/27/18 Due: 08/27/19

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

Phase: N/A Priority: Normal
NCT ID: NCT04042116 Org: User:
Start: 07/29/19 End: 01/31/24 Due: 01/31/25

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Phase: N/A Priority: Normal
NCT ID: NCT02109016 Org: User:
Start: 04/30/14 End: 09/30/16 Due: 09/30/17

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02147990 Org: User:
Start: 06/16/14 End: 08/27/19 Due: 08/27/20

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Phase: N/A Priority: Normal
NCT ID: NCT01124786 Org: User:
Start: 05/31/10 End: 06/30/13 Due: 06/30/14

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02186301 Org: User:
Start: 11/30/14 End: 06/28/17 Due: 06/28/18